by Heidi Hagen and Christophe Suchet | February 11, 2020
This post is the fifth in an eight-part series on data management strategies for personalized therapeutics, such as cell therapies, gene therapies, or neoantigen cancer vaccines.
by Nina Kjellson, Laura Chau, and Amy DuRoss | December 17, 2019
The WoVen Podcast, a series hosted by Nina Kjellson and Laura Chau or Canaan investors, which is an early-stage venture capital firm that partners with founders to build the future of how we live, work, and thrive. Each episode explores specific…
by Marc Puich | November 15, 2019
At Biomanufacturing World Summit this week, leaders at the forefront of producing cell and gene therapies gathered to talk about what’s really required to produce deeply individualized therapeutics at scale. Here are a few of the highlights:
Chain of Identity and Chain of Custody in personalized therapies -- core differences from traditional pharma
by Heidi Hagen | October 30, 2019
In pharmaceutical manufacturing, Chain of Identity and Chain of Custody may not be new -- but in advanced therapy manufacturing, they take on a whole new significance. Why? Because in personalized therapies, a person is a key part of the process.
by Heidi Hagen | October 17, 2019
Why is the distinction between the supply chain and value chain important in cell therapies, gene therapies, and personalized cancer vaccines? As it turns out, it all comes back to the patient.